Evaluation of Efficacy of Montelukast In Rheumatoid Arthritis
PDF Downloads : 42    VIEW PDF

Keywords

Montelukast
Rheumatoid arthritis
CFA (Complete Freund’a adjuvant)

How to Cite

Nimbalkar, M. V. V., Chikte, M. D. S., & Gaikwad, D. P. M. . (2016). Evaluation of Efficacy of Montelukast In Rheumatoid Arthritis. VIMS Health Science Journal, 3(3), 95–98. Retrieved from https://www.vimshsj.edu.in/index.php/main/article/view/142

Abstract

Rheumatoid arthritis (RA) is an autoimmune disorder. It is chronic progressive disease resulting in inflammation and deformities of joints. Being an autoimmune disease, there is lacuna in proper management of the disease. Current options like steroids and DMARD’s (disease modifying anti-rheumatic drugs) are the cornerstone in therapy of the disease, but have their own limitations. This study proves efficacy of montelukast in restricting progression of RA. Montelukast is an antagonist of leukotriene receptor. Arthritis was induced by two methods according to model by intradermal injection of Complete Freund’s Adjuvant and methylated BSA in right hind paw. Macroscopic, inflammatory biometer, X-ray and radiodiagnosis parameters were studied for both models. Hence results of this study clearly indicate that montelukast has promising anti rheumatic activity.

PDF Downloads : 42    VIEW PDF

References

A. J. silman, ‘Epidemiology of rheumatoid arthritis’ APMIS, 102: 7, 721-728,1994.

“Handout on Health: Rheumatoid Arthritis”. National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2015.

Majithia V, Geraci SA, “Rheumatoid Journal of Medicine, 2007, 120(11), 936-939.

Scott DL, Wolfe F, Huizinga TW, “Rheumatoid arthritis”. Lancet 376 (9746), 2010 1094-1108.

K. D. Tripathi, ‘Essential of medical pharmacology by K. D. Tripathi’, JAYPEE- BROTHERS,5 , 205

R. D. Howland, M. J. Mycek, lippincott’s illustrative pharmacology, Lippincott, williams and Wilkins, 3. 318-319.

Mahaboobkkhan RASOOL, Evan Prince SABINA, and Balaji LAVANYA, “Anti-inflammatory Effect of Spirulina fusiformis on Adjuvant-Induced Arthritis in Mice”, Biol. Pharm. Bull. 29(12), 2006, 2483-2487.

Kay McNamee1, Richard Williams 1 and Michael Seed, “Animal models of rheumatoid arthritis: how infor,ative are they?” Eur J Pharmacol. 2015, 759, 278-286. Doi: 10. 1016/j.ejphar.2015.03.047.

TARIQ M. HAQQI, and et al, “Prevention of collagen-induced arthritis in mice by a polyphenolic fraction from green tea”, Proc. Natl. Acad. Sci. USA, 1999,96,4524-4529.

A. M. Bendele “Animal models of rheumatoid arthritis”, J Musculoskel Neuron Interact, 2001,1(4),377-385.

Pierluigi Paggiaro, MD1 and Elena Bacci, MD2, “ Montelukast in Asthma: A Review of its Efficacy and Place in Therapy”, Ther Adv Chronic Dis, 2011, 2(1), 47-58.

J. Alastair Gracie, 1 Rosalyn J. Forsey, 1 woon Ling Chan and et al, “A proinflammatory role for IL-18 in rheumatoid arthritis, J Clin Invest., 1999, 104(10), 1393-1401.

Collagen-induced arthritis, David D Brand 1, 2, Kary A Latham1, 2 & Edward F Rosloniec, Nature Protocols 2, 2007, 1269-1275.

.M Hegen, J C Keith Jr, and et al. ‘Utility of animal models for identification of potential therapeutics for rheumatoid arthritis’, Ann Rheum Dis, 2008,67(11): 1505-15.

Alzabin S, Williams RO, ‘Effector T cells in rheumatoid arthritis: Lessons from animal models’, FEBS letters (Federation of european biochemical societies), 2011, 585(23), 3649-59.

Patil K. R., Patil C. R. and et al. ‘Anti-Arthritic Activity of Bartogenic Acid Isolated from Fruits of Barringtonia racemosa Roxb. (Lecythidaceae)’ Evidence-Based Complementary and Alternative Medicine, 2009,1-7.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.